Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
Links relacionados
- Similares en SciELO
Compartir
Horizonte Médico (Lima)
versión impresa ISSN 1727-558X
Resumen
OSCANOA, Teodoro. Safety of beta-agonists in asthma. Horiz. Med. [online]. 2014, vol.14, n.3, pp.49-55. ISSN 1727-558X.
Beta 2 agonist bronchodilators (β2A) are very important part in the pharmaco therapy of bronchial asthma, a disease that progresses in the world in an epidemic way. The β2A are prescribed to millions of people around the world, there fore the safety aspects is of public interest. Short-Acting β2 Agonists (SABAs), such as albuterol inhaler, according to current evidence, have confirmed their safety when used as a quick-relief or rescue medication. The long-acting β2 agonists (LABAs) are used associated with inhaled corticosteroids as controller drugs for asthma exacerbations, for safety reasons LABAs are used associated with inhaled corticoid.
Palabras clave : Asthma; long-acting beta-2 agonists (LABA); short-acting beta-2 agonists (SABA)s; safety; formoterol; sameterol; albuterol.